Wednesday, October 14, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts

View original at finance.yahoo.com
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts Quick Read Novo Nordisk (NVO) cut Wegovy and Ozempic prices up to 48% in India due to generic semaglutide competition, while shares have fallen 43% over the past year to $36.98 as 2026 guidance signals -5% to -13% adjusted sales growth; the c…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Wegovy HD achieved an average weight loss of 20.7% over 72 weeks

    60% confidence

  • 2026 guidance signals -5% to -13% adjusted sales growth

    60% confidence

  • CagriSema (cagrilintide plus semaglutide) is expected to receive FDA obesity decision around end of 2026/early 2027

    60% confidence

  • Phase 3 data showed 14.2% weight loss in type 2 diabetes patients for CagriSema

    60% confidence

Data points we hold from this source

Novo Nordisk · stock price 52 week low35.12 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts — Source | Via News | Finance Via News